by Peter Ciszewski | Nov 13, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses how X-Linked Retinoschisis (XLRS) is diagnosed. X-linked retinoschisis (XLRS) is an...
by Peter Ciszewski | Nov 13, 2017
Philippe M. Maitre, Executive Vice President, US Operations discusses Onxeo and the company’s focus on orphan oncology products. Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the...
by Peter Ciszewski | Nov 13, 2017
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the potential market for Iomab-B. Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to...
by Peter Ciszewski | Nov 12, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, provides an overview of Fragile X syndrome. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment....
by Peter Ciszewski | Nov 12, 2017
Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company’s focus and how it is developing drugs for patients with rare disorders.
